A promising new development in pancreatic cancer treatment is attracting attention following encouraging clinical results for daraxonrasib, an oral RAS inhibitor designed to target mutations that drive many pancreatic cancers.
The treatment has shown notable results in patients with advanced pancreatic ductal adenocarcinoma (PDAC), including patients whose disease had progressed despite standard chemotherapy. For a cancer that remains one of the most difficult to treat, the findings represent an important step forward in precision oncology.
We asked Professor Roland Andersson, a researcher involved in the EU-funded SHIELD project, for his perspective on the development.
“More than 90% of PDAC patients have RAS mutations,” Professor Andersson explains. “These have been difficult to target beforehand. What we now see is development with quite substantial results.”
In particular, he points to the reported improvement in overall survival among patients with metastatic disease who had already received standard chemotherapy as a significant breakthrough.
But while new targeted treatments are opening up important possibilities for patients with advanced disease, Professor Andersson stresses that treatment advances and earlier diagnosis need to go hand in hand.
“There are principally two ways of improving outcome in PDAC,” he says. “Firstly, early diagnosis. Secondly, targeted and specific therapy like what we now see above. Both are highly needed and should be considered complementary.”
This is particularly relevant because pancreatic cancer is often diagnosed at an advanced stage, when treatment options are more limited. Even patients who undergo surgery with the aim of completely removing the tumour frequently experience recurrence.
The emergence of RAS-targeted therapies therefore raises an intriguing question for the future: could such treatments have an even greater impact if pancreatic cancer were detected before it has spread?
According to Professor Andersson, this is an area worth exploring. Earlier diagnosis could allow patients to benefit from new treatments at a stage when the disease is still potentially treatable with surgery, while targeted therapies could offer new ways of reducing the risk of recurrence.
For a field where progress has historically been difficult, developments such as these offer genuine reasons for optimism, while also underscoring the importance of continuing to pursue both better treatments and earlier detection.